# Shanghai Fosun Pharmaceutical Industrial Development

Source: https://onco.cc/companies/shanghai-fosun-pharmaceutical-industrial-development/  
OnCo record `shanghai-fosun-pharmaceutical-industrial-development` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Shanghai Fosun Pharmaceutical Industrial Development is a China-based pharmaceutical company running 5 late-stage cancer trials of FCN-159 and Test group (Group A): FCN-159 in non-small-cell lung cancer and rare cancers of childhood.

## Summary

Shanghai Fosun Pharmaceutical Industrial Development, based in Shanghai, China, is a pharmaceutical company and part of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. listed as 600196.SH; 02196.HK. Part of the Fosun Pharma group, a China-rooted global pharmaceutical and healthcare group with operations spanning pharmaceuticals, medical devices, diagnostics, healthcare services and pharmaceutical distribution. On ClinicalTrials.gov it is the lead sponsor of 5 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing FCN-159 and Test group (Group A): FCN-159 in non-small-cell lung cancer and rare cancers of childhood. The largest, NCT06569420 (Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC), plans to enrol 275 participants (actual). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
- Tags: ctgov-sponsor
- HQ: Shanghai
- Type: pharma
- Website: https://www.fosunpharma.com
- Ticker: 600196.SH; 02196.HK

## Sources

- Official website: https://www.fosunpharma.com
- ClinicalTrials.gov: trials led by Shanghai Fosun Pharmaceutical Industrial Development: https://clinicaltrials.gov/search?lead=Shanghai%20Fosun%20Pharmaceutical%20Industrial%20Development%20Co.%20Ltd.

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Rare cancers of childhood (NCI PDQ umbrella)](https://onco.cc/cancers/rare-childhood-cancers/)
- trials: [A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC](https://onco.cc/trials/nct07562581/), [FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms](https://onco.cc/trials/nct06858618/), [Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC](https://onco.cc/trials/nct06569420/), [Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1](https://onco.cc/trials/nct04954001/)

---
JSON: https://onco.cc/api/v1/entities/shanghai-fosun-pharmaceutical-industrial-development.json